Screening for Lung Cancer: What Comes Next?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed.

1. Artificial Intelligence and Early Detection of Breast, Lung, and Colon Cancer: A Narrative Review.Cureus · 2025
   Review
2. Exosomal Thomsen-Friedenreich Glycoantigen: A New Liquid Biopsy Biomarker for Lung and Breast Cancer Diagnoses.Cancer research communications · 2024
   Article
3. Artificial intelligence in lung cancer screening: Detection, classification, prediction, and prognosis.Cancer medicine · 2024
   Review
4. Whole-genome DNA methylation and DNA methylation-based biomarkers in lung squamous cell carcinoma.iScience · 2023
   Article
5. Serum RNAs can predict lung cancer up to 10 years prior to diagnosis.eLife · 2022
   Article
6. Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2019
   Review
7. A Diagnostic Panel of DNA Methylation Biomarkers for Lung Adenocarcinoma.Frontiers in oncology · 2019
   Article
8. Exhaled breath analysis for the early detection of lung cancer: recent developments and future prospects.Lung Cancer (Auckland, N.Z.) · 2017
   Review
9. Resource utilization in lung cancer diagnostic procedures: Current use and budget consequences.PloS one · 2017
   Article

Corrections and comments

• Comment on
  Diacetylspermine Is a Novel Prediagnostic Serum Biomarker for Non-Small-Cell Lung Cancer and Has Additive Performance With Pro-Surfactant Protein B.2015

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as